AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer
PICCOLO trial met its primary endpoint of objective response rate (ORR)
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Around 7% of the Indian population suffers from IBS
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
Subscribe To Our Newsletter & Stay Updated